The stratification of patients with cervical adenocarcinoma, regardless of stage, based on the PIK3CA mutation could be implemented in a clinical setting able to perform ddPCR assays on liquid biopsies, and may offer the possibility of tailoring management. This evidence concerns the gene PIK3CA and cervical adenocarcinoma.